Lyell Immunopharma Net Worth
Lyell Immunopharma Net Worth Breakdown | LYEL |
Lyell Immunopharma Net Worth Analysis
Lyell Immunopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lyell Immunopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lyell Immunopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lyell Immunopharma's net worth analysis. One common approach is to calculate Lyell Immunopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lyell Immunopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lyell Immunopharma's net worth. This approach calculates the present value of Lyell Immunopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lyell Immunopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lyell Immunopharma's net worth. This involves comparing Lyell Immunopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lyell Immunopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Lyell Immunopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lyell Immunopharma's net worth research are outlined below:
| Lyell Immunopharma generated a negative expected return over the last 90 days | |
| Lyell Immunopharma has high historical volatility and very poor performance | |
| Lyell Immunopharma has some characteristics of a very speculative penny stock | |
| Lyell Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M. | |
| Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Lyell Immunopharma Director Hans bishop resigns |
Lyell Immunopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lyell Immunopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lyell Immunopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lyell Immunopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyell Immunopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyell Immunopharma backward and forwards among themselves. Lyell Immunopharma's institutional investor refers to the entity that pools money to purchase Lyell Immunopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sc China Holding Ltd | 2024-09-30 | 3 M | Mic Capital Management Uk Llp | 2024-09-30 | 1.7 M | Opaleye Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1 M | Td Asset Management Inc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 901.5 K | Mwg Management Ltd. | 2024-06-30 | 20.2 M | Orland Properties Ltd | 2024-06-30 | 15.1 M |
Follow Lyell Immunopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 257.02 M.Market Cap |
|
Project Lyell Immunopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.35) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.36) | (0.38) |
When accessing Lyell Immunopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lyell Immunopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lyell Immunopharma's profitability and make more informed investment decisions.
Evaluate Lyell Immunopharma's management efficiency
Lyell Immunopharma has return on total asset (ROA) of (0.1912) % which means that it has lost $0.1912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3322) %, meaning that it created substantial loss on money invested by shareholders. Lyell Immunopharma's management efficiency ratios could be used to measure how well Lyell Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.33. The value of Return On Capital Employed is expected to slide to -0.36. At this time, Lyell Immunopharma's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 1 B this year, although the value of Other Assets will most likely fall to about 4.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.61 | 2.30 | |
| Tangible Book Value Per Share | 2.61 | 2.30 | |
| Enterprise Value Over EBITDA | (1.78) | (1.87) | |
| Price Book Value Ratio | 0.74 | 0.71 | |
| Enterprise Value Multiple | (1.78) | (1.87) | |
| Price Fair Value | 0.74 | 0.71 | |
| Enterprise Value | 4.7 B | 4.5 B |
Lyell Immunopharma benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 1.9 K | Revenue 63 K | Quarterly Revenue Growth 0.36 | Return On Equity (0.33) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyell Immunopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyell Immunopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyell Immunopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyell Immunopharma time-series forecasting models is one of many Lyell Immunopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyell Immunopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lyell Immunopharma Earnings per Share Projection vs Actual
Lyell Immunopharma Corporate Management
| Elizabeth Homans | CEO Director | Profile | |
| Richard Goold | Chief Officer | Profile | |
| Stephen Hill | Chief Officer | Profile | |
| Crystal MD | Founder Advisor | Profile | |
| Charles Newton | Chief Officer | Profile | |
| Prof MD | Founder Advisor | Profile | |
| Nellie Dillery | Director Accounting | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.